[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscular-diseases":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":18,"phases":4,"briefSummary":19,"conditions":20,"keywords":30,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":54,"locationsCount":57},"100612219","managed-access-program-for-del-zota-in-participants-with-dmd-mutations-amenable-to-exon-44-skipping-100612219",false,"NCT07250737","Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping","Key Inclusion Criteria\n\nRollover Participants\n\n* Completed Study EXPLORE44-OLE Treatment Period (through W102)\n* No significant tolerability issues with AOC 1044\n\nNew (Non-Rollover) Participants\n\n* Permanently residing in the US and have a US primary health care provider\n* Documented dystrophin gene mutation that is amenable to exon 44 skipping\n* Age 2 or older at the time of consent\n* If previously treated with gene therapy for DMD, treatment and associated immunosuppressive regimen was more than 12 months before consent and in the opinion of the prescriber, participant has had an unsatisfactory treatment response\n\nKey Exclusion Criteria\n\nRollover Participants\n\n• Prescence of any new condition or worsening of existing condition that could affect participant's safety or ability to comply with the program requirements\n\nNew (Non-Rollover) Participants\n\n* Recently treated with or on a clinical study for another investigation drug\n* Serious respiratory or cardiac dysfunction, or nearing end of life\n* Screening laboratory parameters do not meet protocol requirements\n* History of multiple drug allergies or to any component of AOC 1044\n* Participants who discontinued early from the treatment period of EXPLORE44 or EXPLORE44-OLE","MALE","2 Years","EXPANDED_ACCESS","The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.",[21,22,23,24,25,26,27,28,29],"Muscular Disorders, Atrophic","Muscular Diseases","Musculoskeletal Diseases","Neuromuscular Diseases","Nervous System Diseases","Genetic Diseases, Inborn","Genetic Diseases, X-Linked","Muscular Dystrophies","Muscular Dystrophy, Duchenne",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"Avidity","Avidity Biosciences","AOC 1044","AOC 1044-CS1","AOC 1044-CS2","EXPLORE44","EXPLORE44-OLE","Del-zota","delpacibart zotadirsen","DMD","exon skipping therapy","dystrophin","managed access","expanded access","pre-approval access","compassionate use","MAP","EAP","AVAILABLE","2026-06-26",{"date":52,"type":53},"2026-06-29","ACTUAL",{"name":55,"class":56},"Avidity Biosciences, Inc.","INDUSTRY",14,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":85,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100453331","non-invasive-bci-controlled-assistive-devices-100453331","NCT05183152","Non-invasive BCI-controlled Assistive Devices","Non-invasive Brain-computer Interfaces for Control of Assistive Devices","Inclusion Criteria:\n\n1. Able-bodied participants:\n\n   * good general health\n   * normal or corrected vision\n   * no history of neurological\u002Fpsychiatric disease\n   * ability to read and understand English (Research Personnel do not speak Spanish)\n2. Subjects with motor disabilities\n\n   * motor deficits due to: unilateral and bilateral stroke \u002F spinal cord injury \u002F motor neuron diseases (i.e. amyotrophic lateral sclerosis, spino-cerebellar ataxia, multiple sclerosis) \u002F muscular diseases (i.e. myopathy) \u002F traumatic or neurological pain \u002F movement disorders (i.e. cerebral palsy) \u002F orthopedic \u002F traumatic brain injury \u002F brain tumors\n   * normal or corrected vision\n   * ability to read and understand English\n   * ability to provide informed consent\n\nExclusion Criteria:\n\n1. Subjects with motor disabilities\n\n   * short attentional spans or cognitive deficits that prevent the subject from concentrating during the whole experimental session\n   * heavy medication affecting the central nervous system (including vigilance)\n   * concomitant serious illness (e.g., metabolic disorders)\n2. All participants\n\n   * factors hindering EEG\u002FEMG acquisition and the delivery of non-invasive electrical stimulation (e.g., skin infection, wounds, dermatitis, metal implants under electrodes)\n   * criteria identified in safety guidelines for MRI and TMS, in particular metallic implants",true,"ALL","18 Years","80 Years",{"count":70,"type":71},100,"ESTIMATED","INTERVENTIONAL",[74],"NA","Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. Brain-computer interfaces (BCIs) can decode SMRs to control assistive devices and promote functional recovery. Despite rapid advancements in non-invasive BCI systems based on EEG, two persistent challenges remain: First, the instability of SMR patterns due to the non-stationarity of neural signals, which may significantly degrade BCI performance over days and hamper the effectiveness of BCI-based rehabilitation. Second, differentiating MI patterns corresponding to fine hand movements of the same limb is still difficult due to the low spatial resolution of EEG. To address the first challenge, subjects usually learn to elicit reliable SMR and improve BCI control through longitudinal training, so a fundamental question is how to accelerate subject training building upon the SMR neurophysiology. In this study, the investigators hypothesize that conditioning the brain with transcutaneous electrical spinal stimulation, which reportedly induces cortical inhibition, would constrain the neural dynamics and promote focal and strong SMR modulations in subsequent MI-based BCI training sessions - leading to accelerated BCI training. To address the second challenge, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. The investigators study the neuroplastic changes associated with training with the two stimulation modalities.",[77,78,79,22,80,81,82,83,84],"Motor Disorders","Healthy","Spinal Cord Injuries","Motor Neuron Disease","Stroke","Traumatic Brain Injury","Movement Disorders","Multiple Sclerosis",[86,87,88,89,90,91,92,93],"motor deficits","able-bodied, healthy","unilateral and bilateral stroke","spinal cord injury","motor neuron diseases","muscular diseases (i.e. myopathy)","traumatic or neurological pain","movement disorders","RECRUITING","2026-04-27",{"date":97,"type":53},"2026-05-01",{"date":99,"type":53},"2021-06-16",{"date":101,"type":71},"2028-12-30",{"name":103,"class":104},"University of Texas at Austin","OTHER",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":66,"minAge":67,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":72,"phases":114,"briefSummary":116,"conditions":117,"keywords":124,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100564264","phase-1-a-phase-1-study-of-anitocabtagene-autoleucel-for-the-treatment-of-subjects-with-non-oncology-plasma-cell-related-diseases-100564264","NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","Inclusion Criteria:\n\n* Subject must be 18 years of age or older\n* Must have MGFA clinical classification Grades 2-4A at time of screening\n* Subject must have clinically active disease and requiring ongoing therapy for GMG\n* MG-ADL score 6 and QMG score \\>10 at screening\n* GMG specific autoantibodies must be above the reference laboratory ULN\n\nExclusion Criteria:\n\n* Subject is pregnant or breastfeeding\n* Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion\n* Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager\n* Previous thymectomy within 6 months of screening\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator",{"count":113,"type":71},30,[115],"PHASE1","A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.",[22,118,119,120,121,122,123],"Neuromuscular Manifestations","Autoimmune","Autoimmune Diseases","Autoimmune Diseases of the Nervous System","Myasthenia Gravis","Muscle Weakness",[125,126,127,128,129,130,131,132,122,133,134,135,136,137,138,139],"ARC-311","CART","CAR-T","BCMA","Anito-cel","Generalized Myasthenia Gravis","gMG","MG","non-oncology plasma cell","autoimmune","auto-antibody","chimeric antigen receptor","D-Domain chimeric antigen receptor","B-cell maturation antigen (BCMA)","anitocabtagene autoleucel","2026-02-24",{"date":142,"type":53},"2026-02-25",{"date":144,"type":53},"2025-04-30",{"date":146,"type":71},"2028-04",{"name":148,"class":56},"Arcellx, Inc.",13]